|
1.
|
Peters BG: An overview of chemotherapy
toxicities. Top Hosp Pharm Manage. 14:59–88. 1994.
|
|
2.
|
Van Ryckeghem F and Van Belle S:
Management of chemotherapy-induced nausea and vomiting. Acta Clin
Belg. 65:305–310. 2010.
|
|
3.
|
Grunberg SM and Hesketh PJ: Control of
chemotherapy-induced emesis. N Engl J Med. 329:1790–1796. 1993.
|
|
4.
|
Hickok JT, Roscoe JA, Morrow GR, King DK,
Atkins JN and Fitch TR: Nausea and emesis remain significant
problems of chemotherapy despite prophylaxis with
5-hydroxytryptamine-3 antiemetics: a University of Rochester James
P. Wilmot Cancer Center Community Clinical Oncology Program Study
of 360 cancer patients treated in the community. Cancer.
97:2880–2886. 2003.
|
|
5.
|
Hesketh PJ, Grunberg SM, Gralla RJ, et al:
Aprepitant Protocol 052 Study Group: The oral neurokinin-1
antagonist aprepitant for the prevention of chemotherapy-induced
nausea and vomiting: a multinational, randomized, double-blind,
placebo-controlled trial in patients receiving high-dose cisplatin
- the Aprepitant Protocol 052 Study Group. J Clin Oncol.
21:4112–4119. 2003.
|
|
6.
|
Warr DG, Grunberg SM, Gralla RJ, et al:
The oral NK(1) antagonist aprepitant for the prevention of acute
and delayed chemotherapy-induced nausea and vomiting: pooled data
from 2 randomised, double-blind, placebo controlled trials. Eur J
Cancer. 41:1278–1285. 2005.
|
|
7.
|
Warr DG, Hesketh PJ, Gralla RJ, et al:
Efficacy and tolerability of aprepitant for the prevention of
chemotherapy-induced nausea and vomiting in patients with breast
cancer after moderately emetogenic chemotherapy. J Clin Oncol.
23:2822–2830. 2005.
|
|
8.
|
Osoba D: Health-related quality-of-life
assessment in clinical trials of supportive care in oncology.
Support Care Cancer. 8:84–88. 2000.
|
|
9.
|
Barford KL and D’Olimpio JT: Symptom
management in geriatric oncology: practical treatment
considerations and current challenges. Curr Treat Options Oncol.
9:204–214. 2008.
|
|
10.
|
Stokman MA, Spijkervet FK, Boezen HM,
Schouten JP, Roodenburg JL and de Vries EG: Preventive intervention
possibilities in radiotherapy- and chemotherapy-induced oral
mucositis: results of meta-analyses. J Dent Res. 85:690–700.
2006.
|
|
11.
|
Park SB, Krishnan AV, Lin CS, Goldstein D,
Friedlander M and Kiernan MC: Mechanisms underlying
chemotherapy-induced neurotoxicity and the potential for
neuroprotective strategies. Curr Med Chem. 15:3081–3094. 2008.
|
|
12.
|
Navari RM, Reinhardt RR, Gralla RJ, et al:
Reduction of cisplatin-induced emesis by a selective
neurokinin-1-receptor antagonist. L-754, 030 Antiemetic Trials
Group. N Engl J Med. 340:190–195. 1999.
|
|
13.
|
Coates A, Abraham S, Kaye SB, et al: On
the receiving end-patient perception of the side-effects of cancer
chemotherapy. Eur J Cancer Clin Oncol. 19:203–208. 1983.
|
|
14.
|
Griffin AM, Butow PN, Coates AS, et al: On
the receiving end. V: patient perceptions of the side effects of
cancer chemotherapy in 1993. Ann Oncol. 7:189–195. 1986.
|
|
15.
|
Erazo Valle A, Wisniewski T, Figueroa
Vadillo JI, Burke TA and Martinez Corona R: Incidence of
chemotherapy-induced nausea and vomiting in Mexico: healthcare
provider predictions versus observed. Curr Med Res Opin.
22:2403–2410. 2006.
|
|
16.
|
Grunberg SM, Deuson RR, Mavros P, et al:
Incidence of chemotherapy-induced nausea and emesis after modern
antiemetics. Cancer. 100:2261–2268. 2004.
|
|
17.
|
Liau CT, Chu NM, Liu HE, Deuson R, Lien J
and Chen JS: Incidence of chemotherapy-induced nausea and vomiting
in Taiwan: physicians’ and nurses’ estimation vs. patients’
reported outcomes. Support Care Cancer. 13:277–286. 2005.
|
|
18.
|
Majem M, Moreno ME, Calvo N, et al:
Perception of healthcare providers versus patient reported
incidence of chemotherapy-induced nausea and vomiting after the
addition of NK-1 receptor antagonists. Support Care Cancer.
19:1983–1990. 2011.
|
|
19.
|
Hilarius DL, Kloeg PH, van der Wall E, van
den Heuvel JJ, Gundy CM and Aaronson NK: Chemotherapy-induced
nausea and vomiting in daily clinical practice: a community
hospital-based study. Support Care Cancer. 20:107–117. 2012.
|
|
20.
|
Yada T, Kohno D, Maejima Y, et al:
Neurohormones, rikkunshito and hypothalamic neurons interactively
control appetite and anorexia. Curr Pharm Des. May 23–2012.(Epub
ahead of print).
|
|
21.
|
Takeda H, Sadakane C, Hattori T, et al:
Rikkunshito, an herbal medicine, suppresses cisplatin-induced
anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology.
134:2004–2013. 2008.
|
|
22.
|
Takeda H, Muto S, Nakagawa K, Ohnishi S
and Asaka M: Rikkunshito and ghrelin secretion. Curr Pharm Des. May
23–2012.(Epub ahead of print).
|
|
23.
|
Cheng KC, Li YX and Cheng JT: The use of
herbal medicine in cancer-related anorexia/cachexia treatment
around the world. Curr Pharm Des. May 23–2012.(Epub ahead of
print).
|
